Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 3 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Antihypertensives / BP lowering Medicines | Prevention |
Mixed
whyAntihypertensive treatment improved cognitive scores by a small amount (SMD 0.06, moderate certainty) but the reduction in dementia incidence was not statistically significant (OR 0.89, low certainty). The drug-class rankings rest on one trial per class and are described as highly uncertain. |
Cognitive function scores and incident dementia in hypertensive older adults (four RCTs) | meta-analysis | 16,823 | Antihypertensive treatment significantly improved cognitive function scores (SMD, 0.06; 95% CI, 0.03-0.09; P < .001, GRADE moderate certainty) and showed a nonsignificant trend toward reduced dementia incidence (OR, 0.89; 95% CI, 0.76-1.05; P = .172, GRADE low certainty) |
Journal of the American Medical Directors Association
2026 ✓ Peer-reviewed PMID 41962914 |
| Antihypertensives / BP lowering Medicines | Prevention |
Mixed
whyAntihypertensive use tracked lower Alzheimer's risk but not lower non-Alzheimer dementia risk, where treated and untreated hypertension looked the same. A single baseline blood pressure reading predicted neither. |
Alzheimer's and non-Alzheimer dementia | meta-analysis | 31,250 | Untreated vs treated hypertension: Alzheimer's dementia HR 1.42 (95% CI 1.08-1.87) |
Neurology
2024 ✓ Peer-reviewed PMID 39141884 |
| Metformin / antidiabetic Medicines | Prevention |
Mixed
whyThe split inside this one paper is the finding: the 41 observational studies show large benefits (SGLT2i OR 0.56, GLP-1RA OR 0.58) while the 23 randomised trials show no difference. When design and result disagree this cleanly, the trials are the ones to believe. |
Incident dementia | meta-analysis | 3,462,926 | Observational: SGLT2i OR 0.56 (95% CI 0.45-0.69), GLP-1RA OR 0.58 (0.46-0.73) vs non-users; RCTs: no difference |
Alzheimer's Research & Therapy
2024 ✓ Peer-reviewed PMID 39716328 |